Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

NCT04335292 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Osimertinib First-Line
DRUG: Platinum + Pemetrexed Chemotherapy Second-Line
DRUG: Osimertinib Third-Line

Sponsor

Mark Vincent

Collaborators

[object Object]